Glucagon-like peptide 1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, commonly used for blood sugar control, also offer benefits such as weight loss and reduced inflammation. Although ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

New research finds that SGLT-2is and GLP-1RAs are linked to lower risk of COPD exacerbations in patients with Type 2 diabetes ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

Please provide your email address to receive an email when new articles are posted on . GLP-1s reduced depression risk vs. DPP-4 inhibitors but not SGLT2 inhibitors. However, both GLP-1s and SGLT2 ...

The use of GLP-1 receptor agonists, like semaglutide, to treat type 2 diabetes is not associated with an increased risk of ...

and colleagues compared the risk for depression in older adults with T2D initiating treatment with GLP-1 RAs versus sodium-glucose cotransporter-2 inhibitors (SGLT-2is) or DPP-4is in a target ...

1.07 to 2.02). The researchers found no consistent evidence for sex and treatment interactions with GLP-1 receptor agonists (HR, 1.17; 95% CrI, 0.87 to 1.58 for men vs women) or SGLT2 inhibitors ...

and colleagues compared the risk for depression in older adults with T2D initiating treatment with GLP-1 RAs vs sodium-glucose cotransporter-2 inhibitors (SGLT-2is) or DPP-4is in a target trial ...